Neptune Technologies & Bioressources Obtains New Patent Directed to Compositions of Omega-3 Fatty Acid Phospholipids Including Krill Oil

Posted On: October 6, 2011

Neptune Technologies and Bioressources Inc., announces that the U.S. Patent and Trademark Office (“USPTO”) has granted Neptune a new patent covering omega-3 phospholipids comprising polyunsaturated fatty acids, one of the main bioactive ingredients in all recognized Krill Oils. The patent is granted for the U.S. market and is valid until 2025.

Neptune’s recently issued U.S. patent (U.S. No. 8,030,348) covers, regardless of the extraction process, novel omega-3 fatty acid phospholipid compositions suitable for human consumption, synthetic and/or natural, including compositions extracted from marine and aquatic biomasses. The 8,030,348 patent protects Neptune Krill Oil (NKO(R)) and also covers amongst others, oils and powders extracted from krill, containing marine phospholipids bonded to EPA and/or DHA, distributed and/or sold in the U.S. market.

More info

From Issue 15 • Categories: Tags: Aquapreneur, DHA, EPA, fish oil, krill oil, Neptune Technologies & Bioresources, omega 3 • No Comments

Neptune Technologies gains NSF environmental claims “OK”

Posted On: May 13, 2011

NSF International has approved the key environmental claims of krill player Neptune Technologies & Bioressources Inc. following an extensive and rigorous review.

The audit ensured conformance to the International Organization for Standardization (IS0) 14021: Environmental labels and declaration, and the Federal Trade Commission (16 CFR PART 260): Guides for the Use of Environmental Marketing Claims.

“The efforts that Neptune put into having their claims verified is laudable,” said Petie Davis, sustainability manager at NSF International. “They demonstrated that they had the systems, processes, documentation, and data to support all of their product and process claims,” she added.

More info

From Issue 14 • Categories: Tags: Aquapreneur, fish oil, krill oil, Neptune Technologies & Bioresources, NSF • No Comments

Bayer Healthcare’s Arctic Wonder market test succeeds with Neptune Krill Oil, leading to launch

Posted On: April 15, 2011

Neptune Technologies & Bioressources Inc.  announced recently that Bayer Healthcare, LLC Consumer Care Division has formally launched its Arctic Wonder proprietary Neptune Krill Oil (“NKO”) in the United States in March 2011 after a succesful market test.

Bayer’s market test conducted over the last year with NKO® under its Arctic Wonder brand was performed in the US internet direct response e-commerce channel of trade.

“Acasti management team, is delighted by the relationship Neptune has developed with Bayer. This is yet another significant milestone for Neptune’s strategic planning which will help NKO® achieve extensive consumer awareness and appreciation. We are looking forward to a successful long-term collaboration with Bayer”, stated Dr. Tina Sampalis, President of Acasti Pharma.

“The agreement with Bayer, the market test results and the marketing approach for Arctic Wonder NKO® not only create broad consumer awareness, confidence and appreciation but also distinguish NKO® as the superior and prime choice amongst competitor krill oil products”, said Mr. Henri Harland, President and CEO of Neptune.“Arctic Wonder is entering the rapidly growing omega-3 market which has shown a sustained annual growth of 12% according to the Frost and Sullivan Report 2010. The omega-3 category is valued at $1.7 billion and expected to reach $3.5 billion in 2015. We believe the full launch by Bayer of Arctic Wonder will achieve immediate success which will in turn positively influence our growth and increase Neptune’s krill oil market share, reinforcing Neptune’s position as the industry leader and Neptune Krill Oil as the gold standard of quality and efficacy for krill oil products in the market.” he added.

More info

 

From Issue 14 • Categories: Tags: Acasti Pharma, Aquapreneur, Arctic Wonder, commercialize, DHA, EPA, fish oil, functional ingredients, krill oil, marine biotechnology, marine ingredients, Neptune Technologies & Bioresources, NKO, nutraceutical, omega 3, pharmaceutical, seafood byproducts • No Comments

Neptune Technologies & Bioressources Inc. Reports Completion of Acasti Pharma Comparative Benchmarking Program versus Lovaza®

Posted On: December 1, 2010

Neptune Technologies & Bioressources Inc.  subsidiary, Acasti Pharma, reports the completion of its  preclinical program designed to compare the lipid management effects of Acasti’s drug candidate CaPre™ versus prescription drug Lovaza®.  Blood lipids were monitored in two animal models in order to assess and compare the efficacy of CaPre™ and Lovaza® over a 12-week treatment period.

• A low daily human equivalent dose of 1g CaPre™ reduced LDL-C (bad cholesterol) levels by 40% and increased HDL-C (good cholesterol) by 180% in a normal rat model (“SD”) while 4gr of Lovaza® did not show any significant effect.
• An even lower daily human equivalent dose of 0.5g CaPre™ was shown to be as efficient as 4g of Lovaza® in reducing triglycerides levels by 40-50% in obese rats with severe diabetes and high triglycerides (“ZDF”)

“These results suggest that a low (0.5g to 1g) daily dosing of CaPre™ is more effective than 4g Lovaza® in elevating HDL-C and lowering LDL-C and triglycerides.  These effects become even more striking considering that a 1g daily dose of CaPre™ contains 8.9 times less EPA and 11.1 times less DHA than the recommended 4g daily dose of Lovaza®. It is also important to note that the triglycerides reduction was observed only after 4 weeks and was maintained throughout the study suggesting a significant metabolic impact of CaPre™,” said Dr. Bruno Battistini, Senior Director, Pharmaceutical R&D of Acasti.

More info

From Issue 12 • Categories: Tags: Acasti Pharma, Aquapreneur, CaPre, fish oil, krill oil, marine ingredients, Neptune Technologies & Bioresources, omega 3 • No Comments

Neptune Technologies & Bioressources Inc. moving into pharmaceutical market with launch of subsidiary Acasti Pharma Inc.’s Onemia

Posted On: October 29, 2010

Montreal’s Neptune Technologies & Bioressources Inc. said Monday it is moving into the pharmaceutical market with the launch of subsidiary Acasti Pharma Inc.’s Onemia at the Cardiometabolic Health Congress in Boston.

Onemia is a marine-based medical food, approced by regulators for the management of cardiometabolic disorders. It can be taken alone or in combination with prescribed heart drugs. It will be manufactured by Neptune and distributed through doctors initially under subcontract. Acasti is seeking partners to commercialize the product outside the United States.

More info

From Issue 12 • Categories: Tags: Acasti Pharma, Aquapreneur, functional ingredients, krill oil, Neptune Technologies & Bioresources, omega 3, Onemia, pharmaceutical • No Comments

Health Canada approves claims for Neptune Technologies’ krill oil supplement

Posted On: September 30, 2010

Neptune Technologies & Bioressources (Nasdaq:NEPT) (TSX-V:NTB) announced Wednesday that Health Canada has approved therapeutic claims for Neptune Krill Oil (NKO), proving that the supplement is in fact safe and effective on certain diseases.

“Health claims are becoming among the most important drivers influencing the purchasing of Omega-3 supplements worldwide,” said CFO Andre Godin.

If this is indeed true, then NKO supplements will see a jump in sales, as evidence reviewed by Health Canada has led to the approval of the product for a number of health claims including cardiovascular health, inflammation and women’s health.

It was shown that NKO, in conjunction with other therapy, helps reduce the levels of harmful LDL cholesterol and increase the levels of beneficial HDL cholesterol, as well as helps reduce the levels of triglycerides in the body, with between only 2-4 softgels per day.

The supplement also demonstrated that it helps reduce pain associated with osteoarthritis and relieves pre-menstrual symptoms.

The Health Canada review process is considered one of the most rigorous in the world, as it involves an extensive assessment of the accuracy, validity and evidence supporting the proposed health claims.

In June last year, Health Canada approved health claims for omega-3, among which was the claim that products providing 3-10g of fish oil per day, or 6-20 softgels help to reduce serum triglycerides, compared to 4 NKO softgels recently approved for the same indication.

More info

From Issue 11 • Categories: Tags: Aquapreneur, krill oil, marine biotechnology, marine ingredient, marine ingredients, Neptune Technologies & Bioresources, nutraceutical, omega 3 • No Comments

Neptune Technologies & Bioressources profits rise on krill oil success

Posted On: July 22, 2010

Neptune Technologies & Bioressources has recorded continued profits in its first quarter, which the firm says is partly a result of a more widespread recognition of krill oil in the nutraceutical industry.

The Canadian firm reported a 45 percent increase in revenue for the three months ended May 31, 2010 compared to the same period last year. This boosted revenue to $4.2m for the period.

According to the company, the improved results were largely due to an investment in the firm’s manufacturing plant last year, which boosted production performance. However, the results also reflect an increased uptake of krill oil as a source of omega-3.

More info

From Issue 11 • Categories: Tags: fish oil, krill oil, marine ingredient, marine ingredients, Neptune Technologies & Bioresources, omega 3 • No Comments